LMNA and Hutchinson-Gilford progeria syndrome: Subsequently, clinical studies have shown that the FTI lonafarnib improves the lifespan of children with HGPS by ~2.5 years [43–45] and is accompanied by a 35–62% decrease in plasma progerin [46].